INAB

INAB

In8bio Inc

Rev —top 1%5Y
Hold

IN8bio, Inc. is a clinical-stage biopharmaceutical company developing gamma-delta T cell therapies for cancer and autoimmune diseases. Its products include candidates for glioblastoma and hematologic malignancies, along with others targeting various tumors.

⚕️ Healthcare NASDAQ Listed 2021 $ USD
$1,000 invested 5 years ago $3today

Score Overview

1 Year
Score
Net Growth3.98%
Net TrendGrew
Net Income Consistency
Rev Growth
Rev TrendShrank
Revenue Consistency
5 Years
Score
Net Growth-27.39%
Net Trend40%
Net Income Consistency
Rev Growth
Rev TrendNever
Revenue Consistency
All Time
Score
Net Growth-27.39%
Net Trend40%
Net Income Consistency
Rev Growth
Rev TrendNever
Revenue Consistency

See the full market ranking →

In8bio Inc fundamental performance

Across In8bio Inc's full reported history, from 2021 to 2025, revenue held from $ 0.00 to $ 0.00 and net income went from -$ 14M to -$ 19M. Revenue increased in 0% of the years measured; net income in 40%.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-08-12
$ 1.00
1 Year2025-08-12
$ 2.25-55.62%
5 Years2021-08-12
$ 286.80-99.65%
All Time2021-07-30
$ 300.00-99.67%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Year
2026$ 0.00-$ 18M$ 17M
2025$ 0.00-$ 19M$ 27M
2024$ 0.00-$ 30M$ 11M
2023$ 0.00-$ 30M$ 21M
2022$ 0.00-$ 27M$ 18M
IPO2021$ 0.00-$ 14M$ 37M

Explore beyond INAB

You're looking at In8bio Inc. Members apply the same fundamental framework across all 3,860 companies we cover.

$99/year $149 founding price

Unlock Holder Dashboard

30-day money-back guarantee.

Explore other companies